An Integrated Analysis of the Role of Gut Microbiome-Associated Metabolites in the Detection of MASH-Related Cirrhosis
2024

Gut Microbiome and Metabolites in MASH-Related Cirrhosis

Sample size: 90 publication 10 minutes Evidence: moderate

Author Information

Author(s): Xiong Feixiang, Zhang Xuejie, Jiang Yuyong, Meng Peipei, Zhou Yang, Ji Xiaomin, Chen Jialiang, Wu Tong, Hou Yixin, Gao Bei

Primary Institution: Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University

Hypothesis

This study aimed to identify the gut microbiota and metabolites involved in the development of MAFLD in patients.

Conclusion

The study found that gut microbiota and metabolites are associated with MASH-related metabolic dysfunction, suggesting that Prevotella and linolenic acid may be potential targets for treatment.

Supporting Evidence

  • The abundance of Prevotellaceae and Prevotella was lower in MASH and NC samples than in HC samples.
  • Linolenic acid-related metabolite levels were significantly lower in MASH and NC samples.
  • A high abundance of Prevotella was associated with LA-related metabolites and MASH.
  • Alterations in gut microbiota may contribute to the onset of MASH and its progression to cirrhosis.
  • Fecal microbiota transplantation may be a potential treatment option for patients with MASH.

Takeaway

Doctors looked at poop samples from 90 people to see how tiny bugs in our tummy and their food affect liver problems. They found that some good bugs and important fats were missing in people with liver issues.

Methodology

The study used 16S rRNA sequencing and non-targeted LC–MS/MS metabolomics analysis on fecal samples from 90 patients divided into three groups: healthy controls, MASH, and MASH-related cirrhosis.

Potential Biases

Potential biases due to the small sample size and individual differences in demographics.

Limitations

Individual differences such as dietary habits, age, and sex may introduce biases, and further experiments are needed to validate the findings.

Participant Demographics

The study included 90 patients: 30 healthy controls, 30 with MASH, and 30 with MASH-related cirrhosis, with a higher proportion of males among MASH patients (80%).

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/metabo14120681

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication